Close menu




August 18th, 2022 | 10:28 CEST

Defence Therapeutics CEO Sébastien Plouffe on the next steps in the battle against cancer

  • Expert
  • DefenceTherapeutics
  • Cancer
Photo credits: pixabay.com

A publicly traded biotechnology business called Defence Therapeutics is developing new vaccines and antibody-drug conjugates (ADC) products on its own proprietary platform. The ACCUM technology, which enables precise delivery of vaccine antigens or ADCs in their intact form to target cells, forms the basis of Defence Therapeutics' platform. As a result, catastrophic illnesses like cancer and infectious diseases can be combated with greater efficacy and potency. CEO Sébastien Plouffe gives us background on the company's latest development in the battle against cancer.

time to read: 1 minutes | Author: Mario Hose
ISIN: DEFENCE THERAPEUTICS INC | CA24463V1013

Table of contents:


    Dr. Moutih Rafei, Director and VP of research and development, Defence Therapeutics
    "[...] At the end of 2022 or the beginning of 2023, we plan to start a Phase I study around each of our activities against breast cancer and skin cancer. [...]" Dr. Moutih Rafei, Director and VP of research and development, Defence Therapeutics

    Full interview

     

    What is the advantage of the latest discovery from Defence Therapeutics and when do patients benefit from the progress in the battle against cancer?

    ‘The battle against cancer includes multiple but specific strategies directly targeting the tumor itself (e.g., CAR-T or immune-checkpoint blockers). However, tumor regression alone is not enough as the tumor being targeted can re-grow and leads to the formation of metastases all over the body. To limit this outcome, one needs to develop a therapeutic cancer vaccine capable not only of destroying tumor cells, but also eliciting the formation of long-term memory response capable of providing potent protection from subsequent tumor relapses.

    So far, dendritic cell-based vaccines were ineffective at achieving this goal, which is why Defence Therapeutics chose to adopt a different and unconventional approach by reprogramming mesenchymal stromal cells using its Accum technology to obtain powerful antigen presenting cells.

    With such an experimental therapeutic vaccine in hand, Defence is currently preparing an IND submission to initiate a Phase I trial in patients with solid tumors.’

    Sébastien Plouffe, CEO, Defence Therapeutics Inc.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Mario Hose on September 26th, 2022 | 06:34 CEST

    dynaCERT at the IAA TRANSPORTATION: generating more interest in the market every day!

    • Expert
    • Hydrogen
    • dynaCERT

    Last week, the logistics industry meeting took place in Germany. All well-known companies from all parts of the world were represented at the IAA TRANSPORTATION in Hanover. The Canadian hydrogen pioneer dynaCERT was also there again. The technology for retrofitting diesel engines can be used now and today, while many other types of technologies still require costly infrastructures to be put in place. Ed Cordeiro is Director of Sales, Americas, and summarizes his impressions of the event.

    Read

    Commented by André Will-Laudien on September 15th, 2022 | 13:35 CEST

    Fighting Cancer: BioNTech, Defence Therapeutics, Valneva, MorphoSys - Which biotech stock is ahead in Biden's Moonshot?

    • Biotechnology
    • Cancer
    • vaccine

    Since the original launch of the Cancer Moonshot in 2016, the US cancer community has made measurable progress toward three ambitious goals. Namely, accelerating the scientific discovery of cancer, fostering greater collaboration, and improving cancer data sharing. In early 2022, President Biden announced a relaunch of the Cancer Moonshot and named new goals: To cut the cancer death rate in half within 25 years and significantly improve the lives of people with cancer. The initiative is just getting a new lease on life in the United States. Some biotech shares could make significant gains in this environment.

    Read

    Commented by Mario Hose on August 25th, 2022 | 05:07 CEST

    dynaCERT CEO Jim Payne on carbon credits and VERRA

    • Expert
    • dynaCERT
    • Hydrogen

    The Canadian hydrogen company dynaCERT is focused on the development of scalable technologies. In cooperation with VERRA in the USA, a process is currently being developed to certify the savings in energy consumption resulting from the use of dynaCERT products as Carbon Credits in the future. The market is large, so the trade fair 'IAA TRANSPORTATION' in Hannover, Germany, September 20-25, 2022, is eagerly awaited for where the company will make its presence clear. dynaCERT was significantly impacted by Corona lockdowns and has been rallying for the past few days, heading towards pre-Covid-19 pandemic levels, peaking at CAD 1.25. In Canada, more than 6.3 million shares were traded yesterday and at the close of the market, another 1.89 million shares were in the bid at CAD 0.30. CEO Jim Payne told us what the significance of the successful deal with VERRA will be. A taste of what to expect.

    Read